Guardant Raises Guidance as Shield Volume Triples

Guardant Health raised its 2026 revenue guidance to $1.36 billion-$1.37 billion, implying growth of 38% to 40% for the year, up from its prior forecast of 36% to 38%. The liquid-biopsy company's third-quarter revenue reached $361 million, a 36% jump from $265.2 million a year earlier. The growth split sharply between its two businesses: oncology revenue rose 25% to $231.3 million as test volume climbed 58% to 117,000, while screening revenue tied to its Shield colon-cancer test surged 180% to $67.6 million as Shield test volume nearly tripled, up 246% to 83,000. Guardant narrowed its non-GAAP net loss to $38.8 million, or $0.29 per share, from $48.3 million a year earlier, though it remains unprofitable on a GAAP basis with a $124.4 million net loss in the quarter. $GH shares reflect a company whose newer screening line is now growing far faster than its established cancer-testing franchise.